Mp59-13 Long-Term Testosterone Therapy in Men With Functional Hypogonadism Is Associated With Improved Lower Urinary Tract Symptoms and Quality of Life

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Basic Research & Pathophysiology (MP59)1 May 2024MP59-13 LONG-TERM TESTOSTERONE THERAPY IN MEN WITH FUNCTIONAL HYPOGONADISM IS ASSOCIATED WITH IMPROVED LOWER URINARY TRACT SYMPTOMS AND QUALITY OF LIFE Karim Sultan Haider, Ahmad Haider, Gheorghe Doros, and Abdulmaged Traish Karim Sultan HaiderKarim Sultan Haider , Ahmad HaiderAhmad Haider , Gheorghe DorosGheorghe Doros , and Abdulmaged TraishAbdulmaged Traish View All Author Informationhttps://doi.org/10.1097/01.JU.0001009476.18935.3b.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Lower urinary tract symptoms (LUTS) are closely associated with quality of life (QoL). We investigated long-term effects of testosterone therapy (TTh) in men with functional hypogonadism. METHODS: In a registry study, 824 men with functional hypogonadism were followed for a median of 13 and a maximum time of 15 years. 409 men received testosterone undecanoate injections 1000 mg/12 weeks following an initial 6-week interval (T-group), 415 opted against TTh and served as controls (CTRL). Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the two groups. International prostate symptoms score (IPSS) and residual bladder volume (RBV) were assessed at every visit. RESULTS: Baseline age was 57.7±7.0 years in the T-group and 62.7±5.3 years in CTRL (p<0.0001). Mean follow-up was 11.6±3.4 years in the T-group and 11.8±3.4 in CTRL. Median follow-up was 12 years in the T-group and 13 years in CTRL.At baseline, alpha-blockers were used by 41.8% (T-group) and 50.4% (CTRL) (p<0.05), 5α-reductase inhibitors by 2.4% and 8.0% (p<0.0005), and PDE5-Inhibitors by 28.9% and 21.7% (p<0.05).IPSS (baseline: 7.0±3.5) decreased to 1.6±1.6 (p<0.0001) in the T-group in year 15. In CTRL, IPSS (baseline: 4.9±2.0) increased to 13.0±5.2 (p<0.0001). The estimated adjusted difference between groups was -13.3 [95% CI: -13.9; -12.6] (p<0.0001). RBV in the T-group (baseline: 55.5±24.1) decreased to 10.4±1.8 mL (p<0.0001) in year 15. In CTRL, RBV (baseline: 52.5±18.4) increased to 106.0±37.7 mL (p<0.0001). The estimated adjusted difference between groups was -106.8 mL [95% CI: -112.0;-101.7] (p<0.0001).QoL, assessed by the Aging Males' Symptoms scale (AMS), improved from 53.8±9.8 (severe symptoms) to 17.3±0.5 (no symptoms) in the T-group and worsened from 40.7±5.8 (moderate symptoms) to 67.0±5.9 (severe symptoms) in CTRL. The estimated adjusted difference between groups at 15 years was -55.2 [95% CI: -56.7;-53.8] (p<0.0001 for all). CONCLUSIONS: In men with functional hypogonadism, long-term TTh is associated with sustainably improved LUTS over 15 years. This may have contributed to improvements in QoL. In the untreated control group, LUTS and QoL deteriorated. Source of Funding: Data entry was funded by Bayer AG © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e962 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Karim Sultan Haider More articles by this author Ahmad Haider More articles by this author Gheorghe Doros More articles by this author Abdulmaged Traish More articles by this author Expand All Advertisement PDF downloadLoading ...